There are 2 clinical trials
Purpose of this study is to understand the clinical feasibility of duodenal juice diagnosis to screen UICC stage II pancreatic ductal adenocarcinoma patients.
The cancer marker is S100P.. --- S100P ---
Description: We hypothesized that there is a statistically-significant difference between two cohorts. The cancer marker is S100P.Measure: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort Time: 1year
Description: Based on each analyzing result of pancreatic cancer markers and corresponding final diagnosis, a receiver operating characteristic (ROC) is evaluated. A cut-off is then chosen from this ROC curve to maximize both sensitivity and specificity.
The purpose of this study is to verify the discriminatory value of previously identified salivary transcriptome and proteome markers for oral squamous cell cancer in an intended use population of patients with oral lesions suspicious for cancer.
Six pre-specified mRNA markers (IL1b, IL8, SAT, DUSP1, OAZ1 and S100P) are measured by polymerase chain reaction. --- S100P ---
Description: Based on multimarker test scoreMeasure: Test specificity at 90% sensitivity Time: at study completion as well as after model development following enrollment of the first 30 patents with cancer
Description: Based on comparison of cancer and controlsMeasure: Validation of individual mRNA and protein markers Time: After enrollment of 30 patients with cancer
Description: Based on combined sensitivity and specificityMeasure: Validation of a pre-specified multi marker model Time: After enrollment of 30 patients with cancer